Benorylate (Benoral) is the esterification product of paracetamol and acetylsalicylic acid. It has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis.
Benorilate is an esterified aspirin preparation whose antirheumatic properties are reported to be as good as those of aspirin[1]. Benorylate causes a large decrease in the liver's conversion rate of lactate into glucose, an important component of glucose homeostasis. Benorylate also impairs the urea synthesis rate from ammonia, another important function of the liver[2].
Benorylate is probably absorbed as the intact molecule which accounts for its good gastric tolerance[3]. Benorylate could inhibit PG synthesis in laboratory animals and in human tissue[4].
[1]. Croft DN, et al. Gastric bleeding and benorylate, a new aspirin. Br Med J. 1972 Sep 2;3(5826):545-7. [2]. Castell JV, et al. Effects of benorylate and impacina on the metabolism of cultured hepatocytes. Xenobiotica. 1985 Aug-Sep;15(8-9):743-9. [3]. Wright V, et al. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8. [4]. A. Bennett , et al. Inhibition of Prostaglandin Synthesis by Benorylate. Rheumatology, Volume XII, Issue suppl, 1 January 1973, Pages 101-105.